Authors
Latest:
Pharma and AI: 2021 and BeyondFerdi Steinmann looks at pharma's current relationship with AI and how it is set to evolve.
Latest:
Bringing Biosimilars to Market in EuropeIf the life sciences sector can support healthcare professionals to gain confidence in substituting original treatments with new biosimilars, prices will reduce and patient outcomes will be enhanced.
Latest:
How Biopharma BD&L Teams are Enhancing Decision Support CapabilitiesIn the race to bolster pipelines and drive growth, biopharma manufacturers are reexamining traditional practices and reimagining market research protocols.
Latest:
Viable Options: Packaging and Partnering for Successful Storage and Transport of Conventional Cold-Chain Vaccines for Covid-19***Live: Thursday, February 25, 2021 at 11am EST | 8am PST | 4pm GMT | 5pm CET*** As strategic planning among manufacturers and logistics partners commences, this webinar will serve as a platform to discuss service offerings and explore the most effective possible solutions. *** On demand until Feb. 25, 2022***
Latest:
FDA Inspection and Enforcement Developments During the COVID-19 PandemicMitigating the risks of development, authorization, and marketing for new therapies following "new normal" created by COVID-related violations.
Latest:
Remembering That TIME Magazine Issue; Celebrating Progress in Patient EngagementLooking to the past reminds industry of great strides taken in clinical research for patients.
Latest:
The View From the ForefrontMatthew Howes, President at Greater Than One, discusses what to expect in the next twelve months in healthcare marketing.
Latest:
The Recipe for Relief: Overcoming Industry Pain PointsWhy investing in people and training can help drugmakers deal with six pressing challenges in particular in the year ahead.
Latest:
Empowering Prior Authorization ProfessionalsA look at the rise of prior authorization certified specialists (PACS)—and their value in improving patient access and outcomes.
Latest:
Don’t Waste A Crisis: How Paratek is Navigating the Business Implications of the COVID-19 PandemicA look at how pharmaceutical company, Paratek is navigating the launch of a new antibiotic during the COVID-19 pandemic.
Latest:
‘Selling a Vision’: Today’s Playbook for StartupsThe Big Pharma commercialization playbook doesn’t work for emerging life sciences companies bootstrapping their way up. Exploring three strategies that could be the ingredients of a winning formula for startups.
Latest:
Beyond Medicines: Pharma's Journey with Patient Family Advisory CouncilsIncluding patient and family feedback in our discussions will help shape our understanding of their perception of provided care and services and how we operate as a whole.
Latest:
New Technologies Come with New Litigation RisksCybersecurity vulnerabilities embedded in AI and machine learning pose significant litigation risks as life sciences companies move to digital technologies.
Latest:
The Untapped Potential of Behavioral Science in Medical AffairsHistorically, Medical Affairs teams have relied on reporting only empirical evidence such as efficacy and tolerability profiles to influence uptake of a new drug or therapy. Here, Ben Routley and Mark Pringle explore the scope for applying behavioral science techniques to improve the impact of client communications.
Latest:
As Pharma Continues to Adapt to AI, the POSA Standard will Need to Equally AdaptU.S. patent law will have to adapt to the use of AI in the life sciences industry.
Latest:
Executive Summary: Uncovering the Missing Link in AI-Enhanced Field Rep SupportAI-powered knowledge assistants are transforming pharmaceutical sales by providing field reps with instant access to accurate and compliant information, addressing challenges related to information overload and inconsistent messaging.
Latest:
Comparing Three Common Pharma Communication AvenuesPavel Klymenko, Head of Omnichannel at Viseven, compares three top approaches to pharma communication and elucidates which are here to stay.
Latest:
Final ThoughtsThe future of CAR T-cell therapies will continue to improve as they expand to other patients in need.
Latest:
How Biopharma Can Accelerate Innovation and Sustain GrowthThere are clear pathways that biopharma companies can take to sustain growth and remain competitive.
Latest:
How to Stand Out in the Wellness Space as a Pharma BrandKey steps in relationship-building beyond just treatment options.
Latest:
Defending Against Label-Based LawsuitsBest practices for defending against lawsuits based on pharmaceutical labeling, including avenues for early resolution of the case and, as necessary, strategies for developing the best evidence for defense.
Latest:
How COVID-19 Has Affected Launches of New Oncology Therapies in the U.S.Several months into the COVID-19 pandemic, this article takes a look back at how the launches of new oncology therapies have been impacted.
Latest:
IDN Trends, Insights and Strategies Every Manufacturer Should KnowWebinar Date/Time: Thu, Aug 8, 2024 1:00 PM EDT
Latest:
How and Why the New ‘Over-Time’ Is Transforming the Work of Medical AffairsWhat’s next and lasting in engagement for medical affairs and commercial teams isn’t complicated, but a big shift is here to stay, according to analysis of an industry survey.
Latest:
The Tech Perspective: Coordinating a Plan of EngagementDesigning an omnichannel artificial intelligence ecosystem that integrates strategies can boost commercial success for pharma.
Latest:
3 Steps to Supercharge Your Rare Disease Advocacy PartnershipsHow these actions can help brand teams form effective and sustainable relationships with patient communities
